華北製藥(600812.SH)擬引進建信投資對2家全資子公司增資實施市場化債轉股
格隆匯6月29日丨華北製藥(600812.SH)公佈,為積極穩妥降低資產負債率,優化資本結構,公司所屬全資子公司華北製藥河北華民藥業有限責任公司(以下簡稱“華民公司”)及全資子公司華北製藥華勝有限公司(以下簡稱“華勝公司”)(上述兩家公司以下合併或單獨稱為“標的公司”)擬引進建信金融資產投資有限公司(以下簡稱“建信投資”)增資實施市場化債轉股,增資金額合計8.2億元,全部以現金方式增資,增資資金用於償還存量金融機構借款。
其中建信投資向華民公司增資5.2億元,增資完成後建信投資持有華民公司35.859%股權;建信投資向華勝公司增資3億元,增資完成後建信投資持有華勝公司47.739%股權。公司不參與本次增資。本次增資完成後,公司將繼續作為兩家標的公司控股股東,仍然擁有對標的公司的實際控制權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.